A BREAKTHROUGH TREATMENT FOR HEP C

EPCLUSA was the first Hep C therapy proven to effectively treat all six main Hep C genotypes with a simple one-pill, once-a-day treatment regimen for the majority of patients.* (See below for more information on genotypes.) This was a particularly significant advancement for patients with genotype 2 (GT2) or genotype 3 (GT3) who did not previously have a one-pill, once-a-day treatment option.

In clinical studies, EPCLUSA had high overall cure rates of 99% for GT2 patients^† and 95% for GT3 patients.^‡ EPCLUSA was also found to be highly effective in patients with GT1, GT4, GT5, and GT6, with overall cure rates ranging from 97–100%.^§ Cure means the Hep C virus is not detected in the blood when measured three months after treatment is completed.

With EPCLUSA, there’s no interferon and no complex regimens.

*EPCLUSA with ribavirin is recommended for patients with advanced cirrhosis (decompensated).^|| If you take EPCLUSA with ribavirin, you should also read the ribavirin Medication Guide for important pregnancy-related information.

^†In a study of 266 patients with genotype 2 Hep C, with or without prior Hep C treatment, and with or without cirrhosis (compensated), who received either EPCLUSA or sofosbuvir + ribavirin for 12 weeks, 99% (133 out of 134) of patients who received EPCLUSA once daily for 12 weeks were cured.

^‡In a study of 552 patients with genotype 3 Hep C, with or without prior Hep C treatment, and with or without cirrhosis (compensated), who received either EPCLUSA for 12 weeks or sofosbuvir + ribavirin for 24 weeks, 95% (264 out of 277) of patients who received EPCLUSA once daily for 12 weeks were cured. Cure rates for EPCLUSA ranged from 89% (with prior Hep C treatment and with cirrhosis) to 98% (without prior Hep C treatment and without cirrhosis).

^§In a study of 740 patients with genotype 1, 2, 4, 5, or 6 Hep C, with or without prior Hep C treatment, and with or without cirrhosis (compensated), who received either EPCLUSA or placebo for 12 weeks, 98% (323 out of 328) of patients with genotype 1, 100% (116 out of 116) of patients with genotype 4, 97% (34 out of 35) of patients with genotype 5, and 100% (41 out of 41) of patients with genotype 6, who received EPCLUSA once daily for 12 weeks were cured.

These studies did not include patients with advanced cirrhosis (decompensated).^||

^||Advanced cirrhosis (decompensated) is when the liver is extensively scarred and can no longer do its job effectively.

ANOTHER STEP FORWARD IN HEP C TREATMENT

HARVONI and EPCLUSA are powered by sofosbuvir

^†Certain patients will need to have ribavirin added to their regimen.

Not currently working with a Hep C Specialist?
FIND ONE HERE

KNOWING YOUR HEP C GENOTYPE IS IMPORTANT

Just as there are different blood types, there are also different types of Hep C, called genotypes. There are six main genotypes, numbered 1 through 6.

In clinical studies, EPCLUSA was effective in treating patients with all six genotypes—a significant advancement, particularly for patients with genotypes 2 and 3. In the past, treatment regimens for Hep C genotypes 2 and 3 often included multiple separate medicines and complicated dosing. If you have Hep C genotype 1, 4, 5, or 6, learn about another treatment option that may be right for you.

Often people don’t know the genotype of Hep C that they have. But knowing your type of Hep C is important because it helps your Hep C Specialist choose the right treatment for you. To learn more about genotypes, reach out to your Hep C Specialist.

GET STARTED WITH EPCLUSA